Holen Sie sich die Stockscreener-App
4.36
7.43%
-0.35
Schlusskurs vom Vortag:
$4.71
Offen:
$4.69
24-Stunden-Volumen:
928.85K
Relative Volume:
0.54
Marktkapitalisierung:
$608.93M
Einnahmen:
$7.83M
Nettoeinkommen (Verlust:
$-64.92M
KGV:
-8.2311
EPS:
-0.5297
Netto-Cashflow:
$-47.22M
1W Leistung:
-4.18%
1M Leistung:
-8.21%
6M Leistung:
+49.32%
1J Leistung:
+179.49%
1-Tages-Spanne:
$4.325
$4.70
1-Wochen-Bereich:
$4.32
$4.77
52-Wochen-Spanne:
$1.3426
$5.15
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.36 | 657.82M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance
ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo
ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Aclaris Therapeutics Holds Steady Near Mid-Range as Traders Eye Key Support and ResistanceVolume Climax - thelegaladvocate.com
Aclaris Therapeutics (ACRS) Edges Lower Amid Tight Trading RangeHigh Conviction Picks - The Legal Advocate
Aclaris Therapeutics (ACRS) Holds Near Support as Volume Suggests Cautious SentimentCTA Positioning - The Legal Advocate
Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside - TradingView
Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - The Chronicle-Journal
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data - MyChesCo
ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding - TradingView
ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026 - TradingView
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
MSN Money - MSN
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Stifel raises Aclaris Therapeutics price target to $4 on pipeline By Investing.com - Investing.com Nigeria
Stifel raises Aclaris Therapeutics price target to $4 on pipeline - Investing.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - The Manila Times
Aclaris: Q1 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D - Stock Titan
Aclaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Investing News Network
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Moomoo
Aclaris (NASDAQ: ACRS) posts Q1 2026 loss but boosts cash runway - Stock Titan
Aclaris says cash lasts through 2028 with key skin, asthma data due - Stock Titan
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Guggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendation - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim - MarketBeat
Aclaris (ACRS) CMO vesting 36,375 RSUs with 9,330 shares tax withheld - Stock Titan
Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline - MyChesCo
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):